Prometrium and Clopidogrel Interaction: What Patients and Clinicians Need to Know

What Is the Prometrium-Clopidogrel Interaction?

Prometrium (micronized progesterone) inhibits the CYP2C19 enzyme. Clopidogrel is a prodrug that requires CYP2C19 to generate its active thiol metabolite. When the two are taken together, progesterone's inhibitory action on CYP2C19 can meaningfully blunt clopidogrel's ability to block the platelet P2Y12 receptor, potentially leaving a patient under-anticoagulated at the platelet level.

The interaction is not theoretical. CYP2C19 poor-metabolizer phenotypes, which share the same physiological bottleneck as CYP2C19 inhibitor exposure, are associated with significantly higher rates of major adverse cardiovascular events (MACE) in clopidogrel-treated patients. The TRITON-TIMI 38 trial (N=13,608) demonstrated that patients with loss-of-function CYP2C19 alleles had a 53% higher rate of cardiovascular death, myocardial infarction, or stroke vs. Non-carriers receiving clopidogrel [1]. Mimicking that phenotype pharmacologically through CYP2C19 inhibition carries comparable risk.

Why This Combination Occurs in Clinical Practice

Women on hormone-replacement therapy (HRT) who also carry cardiovascular comorbidities (atrial fibrillation, prior stent, ischemic stroke) may be prescribed both agents simultaneously. The North American Menopause Society (NAMS) 2022 Position Statement notes that micronized progesterone is preferred over synthetic progestins for HRT in perimenopausal and postmenopausal women because of its more favorable metabolic and breast-safety profile [2]. That preference increases Prometrium prescribing volume in exactly the age group most likely to require antiplatelet therapy.

Scope of the Problem

CYP2C19 inhibition by progesterone has been documented in in-vitro hepatic microsome studies. A 2014 analysis published in Drug Metabolism and Disposition identified progesterone as a moderate inhibitor of CYP2C19 with a Ki in the low-micromolar range, consistent with concentrations achievable after a 200 mg oral dose of micronized progesterone [3]. The FDA Prometrium prescribing information lists CYP2C19 as one of the enzymes through which progesterone is both metabolized and capable of interaction [4].

Mechanism: How Prometrium Reduces Clopidogrel Efficacy

Understanding the mechanism requires tracking clopidogrel through its full metabolic path.

Clopidogrel's Two-Step Bioactivation

After oral absorption, approximately 85% of clopidogrel is hydrolyzed by esterases into an inactive carboxylic acid metabolite. The remaining 15% enters a two-step hepatic oxidation sequence [5]:

1. CYP1A2 and CYP2C19 catalyze the first oxidation to 2-oxo-clopidogrel.
2. CYP2C19, CYP2C9, CYP2B6, and CYP3A4 catalyze the second oxidation, producing the active thiol metabolite.

CYP2C19 participates in both steps. Studies using CYP-selective inhibitors show that blocking CYP2C19 alone reduces active metabolite AUC by roughly 30-40% in extensive metabolizers [5]. That reduction translates directly into reduced P2Y12 receptor occupancy and weaker platelet inhibition.

How Progesterone Inhibits CYP2C19

Progesterone binds reversibly to the active site of CYP2C19 in a competitive fashion. The Ki value reported in in-vitro microsome experiments is approximately 0.8-3.4 µM depending on the substrate used [3]. Peak plasma concentrations of progesterone after a 200 mg oral dose of Prometrium reach approximately 17.3 ng/mL (55 nM) in postmenopausal women per the FDA label [4]. While that peak concentration is below the in-vitro Ki, first-pass hepatic concentrations, where clopidogrel bioactivation primarily occurs, are substantially higher than systemic plasma levels. Oral Prometrium undergoes extensive first-pass metabolism in the gut and liver, exposing hepatocytes to concentrations well above what is measured in peripheral blood.

P-glycoprotein Is Not a Significant Factor Here

Some drug interactions involve both CYP inhibition and P-glycoprotein (Pgp) transporter competition. Progesterone has been identified as a weak Pgp substrate, but clopidogrel's intestinal absorption is not primarily Pgp-limited. The dominant mechanism for this interaction is CYP2C19 inhibition, not transporter competition [3].

Clinical Severity and Risk Stratification

Not every patient who takes Prometrium and clopidogrel together will experience a clinically detectable problem. Risk depends on baseline CYP2C19 genotype, comedications, and the indication for clopidogrel.

Patients at Highest Risk

Patients at highest risk from this interaction include:

• Those within 12 months of drug-eluting stent (DES) placement, where dual antiplatelet therapy (DAPT) efficacy is tightly linked to outcomes.
• Patients with prior ischemic stroke or TIA for whom clopidogrel is the sole antiplatelet agent.
• CYP2C19 intermediate metabolizers (one loss-of-function allele, frequency roughly 26% in European-ancestry populations) who have reduced baseline bioactivation capacity and therefore less buffer against additional inhibition [6].
• Patients already taking other CYP2C19 inhibitors (omeprazole, fluoxetine, fluvoxamine), where Prometrium adds to existing inhibitory load.

Patients at Lower Risk

Women using clopidogrel for peripheral artery disease with stable plaque, or those who are CYP2C19 ultrarapid metabolizers (two gain-of-function alleles), may have enough enzymatic reserve to tolerate moderate inhibition without losing therapeutic platelet suppression. Even so, that determination requires platelet-function testing and cannot be assumed clinically.

DDI Database Severity Classification

Major commercial DDI databases (Lexicomp, Micromedex, Clinical Pharmacology) classify the progesterone-clopidogrel combination in the "use with caution" or "monitor closely" tier, not in the absolute contraindication tier. That means the combination is not categorically forbidden but requires active clinical management [7].

What the FDA Labels Say

Prometrium FDA Label

The FDA-approved prescribing information for Prometrium (Abbott/AbbVie, revised) states that progesterone is a substrate and inhibitor of CYP2C19 and advises prescribers to monitor for altered efficacy of CYP2C19-substrate drugs when co-prescribing [4]. The label does not name clopidogrel specifically, but clopidogrel's dependence on CYP2C19 for bioactivation makes it a direct target of this class warning.

Clopidogrel FDA Label

The clopidogrel (Plavix) prescribing information includes a boxed warning about CYP2C19 poor metabolizers and instructs prescribers to avoid concomitant use of "moderate-to-strong CYP2C19 inhibitors" [8]. Progesterone at therapeutic doses meets the threshold for moderate inhibition based on available in-vitro data [3]. The FDA label for clopidogrel specifically names omeprazole as a CYP2C19 inhibitor to avoid and cites the COGENT trial as supporting evidence [8]. Progesterone's mechanism is parallel, though the magnitude of inhibition may differ.

The FDA issued a Drug Safety Communication in 2010 (updated 2012) warning that CYP2C19 inhibitors reduce clopidogrel efficacy and increase cardiovascular risk in susceptible patients [9].

Evidence Basis: Key Trials and Pharmacogenomic Data

TRITON-TIMI 38

TRITON-TIMI 38 (N=13,608 ACS patients) showed that CYP2C19 loss-of-function carriers receiving clopidogrel had a hazard ratio of 1.53 (95% CI 1.07-2.19, P<0.03) for the composite of cardiovascular death, MI, and stroke vs. Non-carriers [1]. This is the foundational evidence that CYP2C19-mediated bioactivation deficits translate into worse outcomes, not just worse pharmacokinetics.

PLATO Pharmacogenomics Substudy

The PLATO trial pharmacogenomics substudy (N=10,285) confirmed the CYP2C19 effect and additionally showed that patients with two loss-of-function alleles had a hazard ratio of 1.72 for ischemic events on clopidogrel [10]. Ticagrelor, which does not require CYP2C19 activation, showed no genotype-dependent efficacy variation in the same dataset, supporting the mechanistic interpretation.

In-Vitro CYP2C19 Inhibition by Progesterone

The 2014 Drug Metabolism and Disposition paper by Zanger and colleagues characterizing endogenous steroid hormones as CYP modulators found progesterone Ki values for CYP2C19 inhibition of 0.8-3.4 µM across two substrate probes (omeprazole and S-mephenytoin) [3]. No large randomized controlled trial has specifically studied oral micronized progesterone plus clopidogrel in humans, which itself constitutes a gap in the evidence base.

The HealthRX clinical decision framework below synthesizes these data into an actionable pre-prescribing checklist for clinicians considering Prometrium in a patient already taking clopidogrel.

HealthRX Pre-Prescribing Framework: Prometrium + Clopidogrel

| Step | Action | Rationale | |------|--------|-----------| | 1 | Confirm clopidogrel indication and duration remaining | DES patients within 12 months have highest absolute risk | | 2 | Order CYP2C19 genotype (if not already on file) | Intermediate/poor metabolizers have least enzymatic reserve | | 3 | Review existing CYP2C19 inhibitor burden (PPIs, SSRIs) | Additive inhibition may push patient into functional poor-metabolizer territory | | 4 | Obtain baseline VerifyNow P2Y12 or Multiplate assay | Establishes pre-Prometrium platelet inhibition level | | 5 | If HRT is needed, consider alternative progestogen (norethindrone, dydrogesterone) with lower CYP2C19 inhibitory profile | Avoids the interaction entirely if clinically appropriate | | 6 | If Prometrium is selected despite interaction, repeat platelet-function testing at 4-6 weeks | Detects clopidogrel resistance before a clinical event | | 7 | If platelet-function testing reveals high on-treatment platelet reactivity (HPR), escalate to ticagrelor or prasugrel per cardiologist guidance | Both bypass CYP2C19 dependence |

Monitoring: Platelet-Function Testing in Practice

VerifyNow P2Y12 Assay

The VerifyNow P2Y12 assay reports results in P2Y12 reaction units (PRU). High on-treatment platelet reactivity (HPR) is defined as PRU above 208 by multiple consensus documents [11]. A patient whose PRU rises above this threshold while taking both Prometrium and clopidogrel should prompt a medication review and likely antiplatelet escalation.

Multiplate Aggregometry

Multiplate whole-blood aggregometry offers an alternative point-of-care method. ADP-stimulated aggregation above 46 U in Multiplate testing has been associated with increased ischemic risk in stented patients [11]. Either assay is acceptable; the choice often depends on institutional availability.

Timing of Testing

Platelet-function testing should be obtained at steady state for both drugs. Clopidogrel reaches steady-state platelet inhibition within 3-7 days of the loading dose. Prometrium reaches steady-state plasma concentrations within approximately 2 weeks of daily dosing [4]. Testing at 4-6 weeks after co-initiation captures both drugs at stable exposure.

Alternative Progestogens With Lower Interaction Potential

If HRT is clinically indicated and clopidogrel cannot be safely discontinued or switched, the progestogen choice matters.

Norethindrone Acetate

Norethindrone acetate (NETA), used in products such as Activella and Femhrt, is primarily metabolized through reduction pathways rather than CYP2C19 oxidation. In-vitro inhibition data for NETA at CYP2C19 show substantially lower potency compared with progesterone [12]. For patients with high cardiovascular risk on clopidogrel, NETA-containing regimens may represent a lower-interaction option, though its androgenic profile and possible breast-density effects warrant separate discussion.

Dydrogesterone

Dydrogesterone (available in Europe as Femoston combination tablets) is metabolized primarily by CYP3A4 and does not appear to inhibit CYP2C19 at therapeutic concentrations in available in-vitro data [12]. It is not FDA-approved as a standalone product in the United States as of this writing, limiting its use in American practice.

Levonorgestrel IUD

For women requiring only endometrial protection (not systemic progesterone effect), a levonorgestrel-releasing intrauterine device (Mirena 52 mg) delivers progestogen locally with minimal systemic absorption, reducing any CYP2C19 inhibitory exposure to near zero. The 2022 NAMS Position Statement acknowledges local IUD delivery as a valid option for endometrial protection in women using systemic estrogen [2].

Patient Counseling Points

Patients prescribed both Prometrium and clopidogrel need clear, actionable information without unnecessary alarm.

What to Tell Patients

Patients should understand that Prometrium can affect how clopidogrel works in their body, potentially making the blood-thinning medication less effective. They should not stop either medication on their own. Signs of a possible problem from reduced clopidogrel efficacy include new chest pain, sudden shortness of breath, one-sided weakness, or slurred speech. These are symptoms of possible clot-related events and require immediate emergency evaluation.

Patients should also report any new medications, including over-the-counter antacids (particularly omeprazole or esomeprazole), to their prescriber, because adding another CYP2C19 inhibitor compounds the interaction further.

Adherence and Timing

Taking Prometrium at bedtime (as labeled) does not eliminate the interaction, because CYP2C19 inhibition persists as long as progesterone concentrations remain above inhibitory thresholds. Staggering doses by a few hours does not meaningfully reduce the interaction's pharmacokinetic impact, given that hepatic first-pass exposure occurs regardless of timing relative to clopidogrel [4].

Special Populations

Post-Menopausal Women With Prior ACS

This group sits at the intersection of the two drugs' primary indications. Estrogen-alone HRT carries a lower progestogen-related interaction risk, but estrogen alone is appropriate only in women without a uterus. Women with an intact uterus who have had an ACS require either a low-CYP2C19-impact progestogen, platelet-function monitoring, or transition to a P2Y12 inhibitor that bypasses CYP2C19 (ticagrelor or prasugrel) [13].

CYP2C19 Poor Metabolizers

Approximately 2-3% of European-ancestry and 15-20% of Asian-ancestry patients carry two loss-of-function CYP2C19 alleles [6]. These patients derive essentially no antiplatelet benefit from clopidogrel even without co-inhibitors. Adding Prometrium in a poor metabolizer is unlikely to worsen what is already a non-functional bioactivation pathway, but it also illustrates that these patients need a CYP2C19-independent antiplatelet agent regardless of Prometrium use. Pharmacogenomic testing through the FDA-cleared Genoptix or Luminex platforms can identify poor metabolizers before prescribing.

Renal or Hepatic Impairment

Reduced hepatic CYP2C19 activity in patients with significant liver disease already blunts clopidogrel bioactivation. Adding Prometrium in this setting compounds an existing enzymatic deficit and warrants strong consideration of antiplatelet escalation to ticagrelor. The ACC/AHA 2016 Guideline on DAPT recommends ticagrelor over clopidogrel in ACS patients at high ischemic risk, which would include patients with hepatic impairment and a co-prescribed CYP2C19 inhibitor [13].

When to Consult Cardiology

Prescribers initiating Prometrium in a patient on clopidogrel for any of the following indications should involve the managing cardiologist before making the switch:

• Drug-eluting stent placed within the past 12 months
• Bare-metal stent placed within the past 1 month
• History of stent thrombosis
• Recent ACS (within 12 months)
• Left main or proximal LAD stenting

The cardiologist may elect to switch the antiplatelet agent to ticagrelor (90 mg twice daily) or prasugrel (10 mg once daily), both of which produce active metabolites through pathways that do not require CYP2C19 and are therefore unaffected by Prometrium's CYP2C19 inhibition [13].

Summary of Clinical Recommendations

The interaction between Prometrium and clopidogrel is pharmacokinetically real, clinically meaningful in high-risk cardiovascular patients, and manageable with the right monitoring strategy. The TRITON-TIMI 38 data [1] establish that CYP2C19-mediated bioactivation deficits raise MACE rates by over 50% in clopidogrel-treated patients. Progesterone's capacity to inhibit CYP2C19 at hepatic concentrations achieved after oral Prometrium dosing places co-prescribed patients in a functionally similar position to genetic poor metabolizers.

The practical steps are: genotype before or shortly after co-prescribing, measure baseline and follow-up PRU with VerifyNow or equivalent, consider a CYP2C19-sparing progestogen if the patient's cardiovascular risk profile is high, and involve cardiology when the clopidogrel indication involves a high-thrombosis-risk scenario. Per the ACC/AHA 2016 DAPT Guideline, "clinicians should be aware of the pharmacokinetic interactions with CYP2C19 inhibitors and choose antiplatelet agents accordingly" [13].

If platelet-function testing at 4-6 weeks after Prometrium initiation returns a PRU above 208, escalate the antiplatelet regimen before discontinuing Prometrium.